<DOC>
	<DOC>NCT02586311</DOC>
	<brief_summary>Trial to Evaluate the Efficacy and Safety of a CKD-330 versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy</brief_summary>
	<brief_title>CKD-330 Phase 3 Trial in Amlodipine Non-responder</brief_title>
	<detailed_description>A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a CKD-330 versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy</detailed_description>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Age of 19 or above Essential hypertension with 140mmHg ≤ mean sitSBP &lt; 180mmHg on target arm at Visit 2 Ability to provide written informed consent The difference between arms of sitSBP ≥ 20mmHg and/or sitDBP ≥ 10mmHg at Visit 1 mean sitSBP ≥ 200mmHg and/or mean sitDBP ≥ 120mmHg on target arm at Visit 1 mean sitSBP ≥ 180mmHg and/or mean sitDBP ≥ 120mmHg on target arm at Visit 2 Known or suspected Secondary Hypertension Type I Diabetes Mellitus and Type II Diabetes Mellitus with HbA1c &gt; 9% Patients with severe congestive heart failure(NYHA class III, IV) Patient with ischemic heart disease, Ischemic cardiovascular disease, Valvular heart disease, arrhythmia requiring treatment within 3 months History of cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months History of severe or malignant retinopathy AST/ALT ≥ UNL*3, Serum creatinine ≥ UNL*1.5, K &gt; 5.5mEq/L Patients with acute or chronic inflammatory status requiring treatment Patient who need to take antihypertensive drug besides Investigational products Patient must be treated with medications prohibited for concomitant use during the study period History of angioedema related to ACE inhibitor or angiotensin II receptor blockers History of disability to drug ADME, active inflammatory bowel syndrome within 12months, impaired pancreatic function, GI bleeding, obstructions of urinary tract History of malignant tumor within 5 years Patient who are dependent on drugs or alcohol within 6 months Hypersensitive to Candesartan/Amlodipine Women with pregnant, breastfeeding Patients treated with other investigational product within 30 days at first time taking the investigational product Not eligible to participate for the study at the discretion of investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>